--Scopus BioPharma Inc. today announced that it has filed an amendment to the Current Report on Form 8- K that was filed by the Company on December 27, 2021 with the U.S. Securities and Exchange ...

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet ...

Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, “The IND submission to the FDA for a Phase 1 clinical trial for our lead drug candidate is a key milestone for Scopus.

Scopus BioPharma’s Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus Maintains Approximately 90% Ownership Stake in Duet ...

Today, investors in Scopus Biopharma (NASDAQ: SCPS) and SCPS stock are seeing incredible gains. This stock has moved more than 115% higher at the time of writing on extremely heavy volume.

Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, “We are extremely excited about the forthcoming submission of the IND for the Phase 1 clinical trial for our lead drug candidate.

News provided by Scopus BioPharma Inc. Nov 07, 2023, 9:15 AM ET DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests ...

Short interest in Scopus BioPharma Corp (OOTC:SCPS) decreased during the last reporting period, falling from 280.30M to 275.20M. This put 1.17% of the company's publicly available shares short.

On Thursday, shares of Scopus Biopharma I (NASDAQ: SCPS) experienced volatile short activity. After the activity, the stock price went up +44.85% to $0.3401. The overall sentiment for SCPS has ...

Check out our SCPS stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.